Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function (B-PFSF).
ABSTRACT To develop a screening tool to allow a postmenopausal woman to determine whether to seek evaluation for hypoactive sexual desire disorder (HSDD).
The Brief Profile of Female Sexual Function (B-PFSF) was developed using items from the Profile of Female Sexual Function (PFSF) and the Personal Distress Scale (PDS). Logistic regression analysis was used to select items best able to discriminate between women with HSDD (n = 743) and controls (n = 226) and a screening cut-off score was identified. Cross-validation analyses were conducted using PFSF and PDS responses from an independent group of 147 HSDD women and 104 controls. Forty cognitive interviews were additionally conducted to assess validity of the final tool.
A seven-item instrument was found to provide good discrimination between postmenopausal women with HSDD and controls and to be a reliable and valid tool. Ninety-six percent of women with HSDD and 97% of control women in the independent validation were classified correctly using the identified cut-off score. In the cognitive interviews, all women stated that the questionnaire was easy to complete and covered relevant aspects of sexual function.
The Brief Profile of Female Sexual Function (B-PFSF) is psychometrically valid and appropriate for use as a self-administered screening tool.
- SourceAvailable from: Sidney H Kennedy[Show abstract] [Hide abstract]
ABSTRACT: Sexual dysfunction is a significant issue for many individuals. This can be the result of existing disorders, side effects of medications, or both. In order to effectively assess and, if appropriate, manage sexual dysfunction in various populations, it is important to consider the use of validated instruments that can provide a baseline to detect dysfunction and measure change over time. This review will assess the psychometric properties of scales (self-report and interview-based) that have been used in community, psychiatric, and gender-specific populations, with a particular emphasis on depressed patients before and during antidepressant therapy. Key considerations for scale selection and development are also discussed.Journal of psychosomatic research 01/2011; 70(1):99-109. DOI:10.1016/j.jpsychores.2010.05.009 · 2.84 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Complaints of decreasing sexual desire in women are common. Hypoactive Sexual Desire Disorder (HSDD) is defined as the loss of sexual desire, not attributable to any other medical cause, which results in marked personal distress and is the most frequently diagnosed female sexual dysfunction. Because urologists treat women for a variety of pelvic and vaginal disorders they should feel comfortable discussing female sexual issues and take the important opportunity to help women with HSDD. Taking a good sexual history and performing a proper exam are of utmost importance when evaluating women with low sexual desire. Unfortunately there is a paucity of literature within the urologic community on this topic*likely due to a lack of awareness among physicians. Herein we review the literature of the past decade on HSDD and provide the practitioner with the basic information needed to diagnose and treat HSDD. We discuss the use of testosterone as well as potential new therapies that are currently in development. Despite the prevalence of this distressing disease, there remains a lack of widely available and accepted treatments. Nevertheless, by better understanding HSDD, urologists can play a vital role in improving the sexual health of women with female sexual dysfunction.
- [Show abstract] [Hide abstract]
ABSTRACT: The recent recognition of the high prevalence of sexual dysfunctions and disorders in our society, along with the substantial investment of the pharmaceutical industry in the field of sexual functioning, has resulted in a significant expansion in the development of valid and reliable measures of sexual function/dysfunction. The instruments tend to be brief self-report inventories, typically requiring 10-20 min of patient time for completion. Most measures were initially developed as screening and outcomes measures for use in clinical drug trials of new treatments for sexual dysfunction, but are beginning to see more widespread use in the clinic. All these instruments must adhere to recently prescribed rigorous guidelines set forth by the Food and Drug Administration, and have been demonstrated to be valid and reliable indicators of the status and quality of sexual functioning in both men and women. The constructs that form the framework of our diagnostic system for sexual dysfunctions are not amenable to direct physical measurement, so that currently they must be assessed via these self-report scales. Although not as precise as physical measures, these inventories do an admirable job of quantifying and registering sexual functioning status in a concise and reliable manner, and have become indispensable tools in our clinical and research programs.International journal of impotence research 01/2008; 20(1):35-44. DOI:10.1038/sj.ijir.3901591 · 1.37 Impact Factor